TSHA-102 program reaches milestone as Taysha Gene Therapies Inc. finalizes REVEAL and ASPIRE dosing

TSHA-102 program reaches milestone as Taysha Gene Therapies Inc. finalizes REVEAL and ASPIRE dosing
Taysha finishes pivotal TSHA-102 trials

Taysha Gene Therapies Inc. delivered its second quarter 2026 earnings report and announced a major development in its TSHA-102 gene therapy program.

The company confirmed that dosing has been completed in both the REVEAL pivotal study and the ASPIRE trial, key milestones for its pipeline. Positive results from these clinical efforts were noted, signaling progress toward potential regulatory submissions and commercialization. Taysha Gene Therapies, Inc. stated it continues executing its strategic plan for TSHA-102 to address significant unmet medical needs.

Earlier this year, Taysha Gene Therapies secured a commercial supply agreement with Catalent for the TSHA-102 program, strengthening its manufacturing capabilities through the new partnership (read more). Ahead of this quarter's announcement, shares of Taysha Gene Therapies rose 6.7% in anticipation of the Q2 2026 earnings and corporate update (details here). The company continues to focus on advancing its gene therapy pipeline in line with earlier strategic moves.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.